RBC Capital Reaffirms Their Buy Rating on uniQure (QURE)

In a report issued on February 25, Luca Issi from RBC Capital maintained a Buy rating on uniQure (QUREResearch Report), with a price target of $53.00. The company’s shares closed last Friday at $16.87, close to its 52-week low of $15.01.

According to, Issi ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -27.4% and a 21.6% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Crispr Therapeutics AG, and Ionis Pharmaceuticals.

uniQure has an analyst consensus of Strong Buy, with a price target consensus of $58.50, which is a 263.4% upside from current levels. In a report issued on February 25, Credit Suisse also maintained a Buy rating on the stock with a $53.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $38.80 and a one-year low of $15.01. Currently, uniQure has an average volume of 647.7K.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Read More on QURE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More